Sarda Proteins (519242) 주식 개요사르다 프로틴은 인도에서 식용유와 농산물을 거래하는 회사입니다. 자세히 보기519242 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적6/6재무 건전성4/6배당0/6강점지난 1년간 수익이 12407.8% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(₹878M)주식은 유동성이 매우 낮습니다지난 1년 동안 주주가 크게 희석되었습니다.의미 있는 수익이 없습니다(₹162M)모든 위험 점검 보기519242 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW496,966 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG496,966 investors already sharing narrativesYour Fair Value₹Current Price₹97.7848.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m563m2016201920222025202620282031Revenue ₹562.7mEarnings ₹22.2mAdvancedSet Fair ValueView all narrativesSarda Proteins Ltd 경쟁사MRP AgroSymbol: BSE:543262Market cap: ₹1.1bRukmani Devi Garg Agro ImpexSymbol: BSE:544552Market cap: ₹944.9mChandrima MercantilesSymbol: BSE:540829Market cap: ₹2.0bGramevaSymbol: BSE:539120Market cap: ₹451.9m가격 이력 및 성과Sarda Proteins 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹97.7852주 최고가₹144.3052주 최저가₹59.95베타-2.491개월 변동4.99%3개월 변동15.74%1년 변동-32.24%3년 변동130.07%5년 변동232.59%IPO 이후 변동866.21%최근 뉴스 및 업데이트공고 • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).공고 • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.더 많은 업데이트 보기Recent updates공고 • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).공고 • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Nov 05Sarda Proteins Ltd to Report Q2, 2026 Results on Nov 14, 2025Sarda Proteins Ltd announced that they will report Q2, 2026 results on Nov 14, 2025공고 • Aug 12Sarda Proteins Ltd to Report Q1, 2026 Results on Aug 14, 2025Sarda Proteins Ltd announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jul 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 23Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • May 19Full year 2025 earnings released: EPS: ₹0.03 (vs ₹0.11 in FY 2024)Full year 2025 results: EPS: ₹0.03 (down from ₹0.11 in FY 2024). Revenue: ₹241.9m (up ₹229.0m from FY 2024). Net income: ₹51.0k (down 74% from FY 2024). Profit margin: 0% (down from 1.5% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 156 percentage points per year, which is a significant difference in performance.공고 • May 13Sarda Proteins Ltd to Report Q4, 2025 Results on May 15, 2025Sarda Proteins Ltd announced that they will report Q4, 2025 results on May 15, 2025New Risk • Mar 20New major risk - Revenue and earnings growthEarnings have declined by 5.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.2% per year over the past 5 years. Market cap is less than US$10m (₹215.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹241m revenue, or US$2.8m).Board Change • Mar 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Jan 13Sarda Proteins Ltd to Report Q3, 2025 Results on Jan 17, 2025Sarda Proteins Ltd announced that they will report Q3, 2025 results on Jan 17, 2025공고 • Oct 26Sarda Proteins Ltd to Report Q2, 2025 Results on Nov 08, 2024Sarda Proteins Ltd announced that they will report Q2, 2025 results on Nov 08, 2024공고 • Sep 11Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024, at 16:00 Indian Standard Time.Reported Earnings • Aug 14First quarter 2025 earnings released: ₹0.46 loss per share (vs ₹0.01 loss in 1Q 2024)First quarter 2025 results: ₹0.46 loss per share (further deteriorated from ₹0.01 loss in 1Q 2024). Net loss: ₹801.0k (loss widened ₹776.0k from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.공고 • Aug 10+ 1 more updateSarda Proteins Ltd Announces Resignation of Mahavir Pratap Sharma as Independent Director, Effective August 11, 2024Sarda Proteins Ltd. announced that the Company has received Resignation letter from Mr. Mahavir Pratap Sharma, Independent Director of the Company, informing about his resignation from the post of Independent Director of the Company due to some personal and unavoidable reason from the said position with effect from August 11, 2024.공고 • Jul 31+ 1 more updateSarda Proteins Ltd Receives Resignation from Amit Kumar Modi as Company Secretary & Compliance OfficerSarda Proteins Ltd. received Resignation letter dated 31 July, 2024 from Mr. Amit Kumar Modi, Company Secretary & Compliance Officer of the Company informing about his resignation from the post of Company Secretary & Compliance Officer of the Company due to some personal and unavoidable reason with effect from the closure of business hours of 31 July, 2024.공고 • Jul 17+ 1 more updateSarda Proteins Ltd Approves Board ChangesSarda Proteins Ltd. at its Board of Directors of the Company in their meeting held on 17 day of July, 2024, approved the resignation of Mrs. Vanita Bhanot from the post of Non-Executive Director, effective from July 17, 2024. The board further announced the appointment of Mr. Chintan Umeshbhai Bhatt as the Additional Director (Independent), Mr. Dhairyakumar Mohanbhai Thakkar as the Additional Director (Independent), Mrs. Dharaben Piyushkumar Patel, as the Additional Director (Non-Executive), effective from July 17, 2024. Mr. Chintan Umeshbhai Bhatt is Practicing Company Secretary. He is Associate memberof the Institute of Company Secretaries of India. He is Bachelor of Law (LL.B.), Commerce graduate (B.Com), Diploma in Tax Practice (DTP) and Diploma in Labour Practice (DLP) awarded by Gujarat University. He is having more than 4 years of experience in the field of Corporate Law and Advisory Services. Mr. Dhairyakumar Mohanbhai Thakkar is a Qualified Company Secretary from the Institute of Company Secretaries of India. He has an experience of more than 10 years in the field of Company Law matters and other corporate matters. Mrs. Dharaben Piyushkumar Patel is a commerce graduate with more than 10 years of experience in the business administration and business management. Terms of Appointment: To hold office till the upcoming Annual General Meeting of the company.공고 • Jul 15Sarda Proteins Ltd Announces Resignation of Shipra Gandhi as Chief Financial OfficerSarda Proteins Ltd. has received resignation letter dated 15t July, 2024 from Mrs. Shipra Gandhi, Chief Financial Officer (CFO) of the company informing about her resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from the closure of business hours of 15th July, 2024.공고 • Jun 25Sarda Proteins Ltd Appoints Khilan Hareshbhai Savaliya as Additional Director (Non-Executive)Sarda Proteins Ltd. at its board of directors meeting held on June 24, 2024, approved appointment of Mr. Khilan Hareshbhai Savaliya (DIN: 08790209) as the Additional Director (Non-Executive)' of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, with effect from 24th day of June, 2024. Terms of Appointment: To hold office till the ensuing Annual General Meetingof the company. With an experience of 3+ years in the field of Turnkey Project Management, Mr. Khilan Hareshbhai Savaliya brings a wealth of knowledge and productivity to the organization.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mahavir Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • May 31Sarda Proteins Ltd Appoints Chirag Shantilal Thumar as Additional Executive DirectorSarda Proteins Ltd. Board of Directors of the Company in meeting held on 28 day of May, 2024, approved the appointment of Mr. Chirag Shantilal Thumar as the Additional Director (Executive) of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, effective 28th May, 2024.Recent Insider Transactions • May 28MD & Director recently sold ₹3.0m worth of stockOn the 24th of May, Deepak Data sold around 35k shares on-market at roughly ₹84.58 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Deepak's only on-market trade for the last 12 months.Reported Earnings • May 02Full year 2024 earnings released: EPS: ₹0.11 (vs ₹0.19 loss in FY 2023)Full year 2024 results: EPS: ₹0.11 (up from ₹0.19 loss in FY 2023). Revenue: ₹14.6m (down 75% from FY 2023). Net income: ₹194.0k (up ₹524.3k from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.공고 • Apr 22Sarda Proteins Ltd to Report Q4, 2024 Results on Apr 30, 2024Sarda Proteins Ltd announced that they will report Q4, 2024 results on Apr 30, 2024Board Change • Feb 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.04 (vs ₹0.01 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.04 (up from ₹0.01 in 3Q 2023). Revenue: ₹10.4m (down 54% from 3Q 2023). Net income: ₹69.0k (up 306% from 3Q 2023). Profit margin: 0.7% (up from 0.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 06Sarda Proteins Ltd to Report Q3, 2024 Results on Feb 13, 2024Sarda Proteins Ltd announced that they will report Q3, 2024 results on Feb 13, 2024공고 • Nov 10Sarda Proteins Ltd Announces Resignation of Somya Data as Chief Financial OfficerSarda Proteins Ltd. announced that it has received Resignation letter dated 08t November, 2023. from. Mr. Somya Data, Chief Financial Officer (CFO) of the Company informing about his resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from closure of business hours of November 30, 2023.Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹0.03 loss per share (vs ₹0.02 profit in 2Q 2023)Second quarter 2024 results: ₹0.03 loss per share (down from ₹0.02 profit in 2Q 2023). Revenue: ₹413.0k (down 99% from 2Q 2023). Net loss: ₹51.0k (down 289% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.공고 • Oct 31Sarda Proteins Ltd to Report Q2, 2024 Results on Nov 07, 2023Sarda Proteins Ltd announced that they will report Q2, 2024 results on Nov 07, 2023공고 • Aug 16Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.공고 • Aug 08Sarda Proteins Ltd to Report Q1, 2024 Results on Aug 14, 2023Sarda Proteins Ltd announced that they will report Q1, 2024 results on Aug 14, 2023New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹58m revenue, or US$706k). Market cap is less than US$10m (₹79.4m market cap, or US$967.3k). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).Reported Earnings • Jun 04Full year 2023 earnings released: ₹0.19 loss per share (vs ₹1.78 profit in FY 2022)Full year 2023 results: ₹0.19 loss per share (down from ₹1.78 profit in FY 2022). Revenue: ₹59.6m (down 45% from FY 2022). Net loss: ₹331.0k (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 24Sarda Proteins Ltd to Report Q4, 2023 Results on May 30, 2023Sarda Proteins Ltd announced that they will report Q4, 2023 results on May 30, 2023Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹55.35, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 91% over the past year.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹49.69, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 30x in the Consumer Retailing industry in India. Total returns to shareholders of 51% over the past year.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹56.55, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 418% over the past three years.Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.32 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.01 (down from ₹0.32 in 3Q 2022). Revenue: ₹22.7m (down 17% from 3Q 2022). Net income: ₹17.0k (down 97% from 3Q 2022). Profit margin: 0.1% (down from 2.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jan 31Sarda Proteins Ltd Announces Chief Financial Officer ChangesBoard of Directors of the Sarda Proteins Ltd, at its meeting held on, 30th January, 2023 has appointed Mr. Somya Data as the Chief Financial Officer (CFO) of the Company with effect from 01st February, 2023. Reason for Change: Due to resignation tendered by Mr. Himanshu Gupta, the Board has decided to appoint Mr. Somya Data as the Chief Financial Officer (CFO) of the company. Date of Appointment: With effect from 01st February, 2023 Qualification and Professional Experience: He is a graduate in Commerce from University of Rajasthan and is also CMA-Inter qualified from the Institute of Cost Accountants of India. He hasimmense knowledge of Financial Planning, Management of Financial Risks, Book Keeping, Financial Reporting, Indian Accounting Standards and Cost Accounting Standards.공고 • Jan 24Sarda Proteins Ltd to Report Q3, 2023 Results on Jan 30, 2023Sarda Proteins Ltd announced that they will report Q3, 2023 results on Jan 30, 2023공고 • Jan 20Sarda Proteins Ltd Announces Resignation of Himanshu Gupta as Chief Financial Officer, Effective 30 January 2023Sarda Proteins Ltd. announced that the company has received resignation letter dated 19 January 2023 from Mr. Himanshu Gupta, chief financial officer (CFO) of the company informing about his resignation from the post of chief financial officer (CFO) due to some personal reasons with effect from closure of business hours of 30 January 2023.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹60.35, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 453% over the past three years.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹90.90, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 41x in the Consumer Retailing industry in India. Total returns to shareholders of 732% over the past three years.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹123, the stock trades at a trailing P/E ratio of 60.4x. Average trailing P/E is 45x in the Consumer Retailing industry in India. Total returns to shareholders of 1,029% over the past three years.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹163, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 37x in the Consumer Retailing industry in India. Total returns to shareholders of 1,390% over the past three years.Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.14 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (up from ₹0.14 loss in 2Q 2022). Revenue: ₹27.9m (up 274% from 2Q 2022). Net income: ₹27.0k (up ₹266.0k from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 161% per year, which means it is tracking significantly ahead of earnings growth.공고 • Oct 13Sarda Proteins Ltd to Report Q2, 2023 Results on Oct 19, 2022Sarda Proteins Ltd announced that they will report Q2, 2023 results on Oct 19, 2022Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.30, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 297% over the past three years.공고 • Aug 06Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022, at 12:30 Indian Standard Time.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹32.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 27x in the Consumer Retailing industry in India. Total returns to shareholders of 213% over the past three years.공고 • Jul 29Sarda Proteins Limited to Report Q1, 2023 Results on Aug 05, 2022Sarda Proteins Limited announced that they will report Q1, 2023 results on Aug 05, 2022Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 22x in the Consumer Retailing industry in India. Total returns to shareholders of 150% over the past three years.공고 • May 19Sarda Proteins Limited to Report Q4, 2022 Results on May 27, 2022Sarda Proteins Limited announced that they will report Q4, 2022 results on May 27, 2022Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.17 loss in 3Q 2021). Revenue: ₹27.4m (up 492% from 3Q 2021). Net income: ₹560.0k (up ₹854.0k from 3Q 2021). Profit margin: 2.0% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates.Board Change • Sep 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Jun 27Full year 2021 earnings released: ₹0.12 loss per share (vs ₹0.19 profit in FY 2020)The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: ₹114.4m (up 112% from FY 2020). Net loss: ₹202.0k (down 161% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹17.87, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 276% over the past three years.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹12.12, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 155% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.17 loss per share (vs ₹0.56 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.63m (down 67% from 3Q 2020). Net loss: ₹294.0k (down 131% from profit in 3Q 2020).공고 • Feb 04Sarda Proteins Ltd. to Report Q3, 2021 Results on Feb 12, 2021Sarda Proteins Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 16% share price gain to ₹10.00, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 23x. This compares to an average P/E of 19x in the Consumer Retailing industry in India. Total return to shareholders over the past year is a loss of 8.4%.공고 • Nov 03Sarda Proteins Ltd. to Report Q2, 2021 Results on Nov 09, 2020Sarda Proteins Ltd. announced that they will report Q2, 2021 results on Nov 09, 2020공고 • Aug 25Sarda Proteins Ltd. to Report Q2, 2020 Results on Sep 02, 2020Sarda Proteins Ltd. announced that they will report Q2, 2020 results on Sep 02, 2020주주 수익률519242IN Consumer RetailingIN 시장7D5.0%-1.5%-0.06%1Y-32.2%-1.5%-0.2%전체 주주 수익률 보기수익률 대 산업: 519242은 지난 1년 동안 -1.5%의 수익을 기록한 Indian Consumer Retailing 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 519242은 지난 1년 동안 -0.2%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 519242's price volatile compared to industry and market?519242 volatility519242 Average Weekly Movementn/aConsumer Retailing Industry Average Movement6.5%Market Average Movement6.2%10% most volatile stocks in IN Market9.2%10% least volatile stocks in IN Market3.9%안정적인 주가: 519242의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine 519242의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19912Chirag Thumarwww.sardaproteins.com사르다 프로테인은 인도에서 식용유와 농산물을 거래하는 회사입니다. 머스타드 오일과 머스타드 오일 케이크, 콩 정제유, 그리고 기름 종자, 곡물, 식용유와 같은 농산물을 거래하고 있습니다. 이 회사는 인력 서비스도 제공합니다.더 보기Sarda Proteins Ltd 기초 지표 요약Sarda Proteins의 순이익과 매출은 시가총액과 어떻게 비교됩니까?519242 기초 통계시가총액₹877.66m순이익 (TTM)₹6.38m매출 (TTM)₹161.58m137.6x주가수익비율(P/E)5.4x주가매출비율(P/S)519242는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표519242 손익계산서 (TTM)매출₹161.58m매출원가₹154.78m총이익₹6.80m기타 비용₹422.00k순이익₹6.38m최근 보고된 실적Mar 31, 2026다음 실적 발표일Jul 15, 2026주당순이익(EPS)0.71총이익률4.21%순이익률3.95%부채/자본 비율5.1%519242의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/14 00:09종가2026/07/13 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sarda Proteins Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
공고 • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026
Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
공고 • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026
Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Nov 05Sarda Proteins Ltd to Report Q2, 2026 Results on Nov 14, 2025Sarda Proteins Ltd announced that they will report Q2, 2026 results on Nov 14, 2025
공고 • Aug 12Sarda Proteins Ltd to Report Q1, 2026 Results on Aug 14, 2025Sarda Proteins Ltd announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jul 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 23Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • May 19Full year 2025 earnings released: EPS: ₹0.03 (vs ₹0.11 in FY 2024)Full year 2025 results: EPS: ₹0.03 (down from ₹0.11 in FY 2024). Revenue: ₹241.9m (up ₹229.0m from FY 2024). Net income: ₹51.0k (down 74% from FY 2024). Profit margin: 0% (down from 1.5% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 156 percentage points per year, which is a significant difference in performance.
공고 • May 13Sarda Proteins Ltd to Report Q4, 2025 Results on May 15, 2025Sarda Proteins Ltd announced that they will report Q4, 2025 results on May 15, 2025
New Risk • Mar 20New major risk - Revenue and earnings growthEarnings have declined by 5.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.2% per year over the past 5 years. Market cap is less than US$10m (₹215.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹241m revenue, or US$2.8m).
Board Change • Mar 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Jan 13Sarda Proteins Ltd to Report Q3, 2025 Results on Jan 17, 2025Sarda Proteins Ltd announced that they will report Q3, 2025 results on Jan 17, 2025
공고 • Oct 26Sarda Proteins Ltd to Report Q2, 2025 Results on Nov 08, 2024Sarda Proteins Ltd announced that they will report Q2, 2025 results on Nov 08, 2024
공고 • Sep 11Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024, at 16:00 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2025 earnings released: ₹0.46 loss per share (vs ₹0.01 loss in 1Q 2024)First quarter 2025 results: ₹0.46 loss per share (further deteriorated from ₹0.01 loss in 1Q 2024). Net loss: ₹801.0k (loss widened ₹776.0k from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.
공고 • Aug 10+ 1 more updateSarda Proteins Ltd Announces Resignation of Mahavir Pratap Sharma as Independent Director, Effective August 11, 2024Sarda Proteins Ltd. announced that the Company has received Resignation letter from Mr. Mahavir Pratap Sharma, Independent Director of the Company, informing about his resignation from the post of Independent Director of the Company due to some personal and unavoidable reason from the said position with effect from August 11, 2024.
공고 • Jul 31+ 1 more updateSarda Proteins Ltd Receives Resignation from Amit Kumar Modi as Company Secretary & Compliance OfficerSarda Proteins Ltd. received Resignation letter dated 31 July, 2024 from Mr. Amit Kumar Modi, Company Secretary & Compliance Officer of the Company informing about his resignation from the post of Company Secretary & Compliance Officer of the Company due to some personal and unavoidable reason with effect from the closure of business hours of 31 July, 2024.
공고 • Jul 17+ 1 more updateSarda Proteins Ltd Approves Board ChangesSarda Proteins Ltd. at its Board of Directors of the Company in their meeting held on 17 day of July, 2024, approved the resignation of Mrs. Vanita Bhanot from the post of Non-Executive Director, effective from July 17, 2024. The board further announced the appointment of Mr. Chintan Umeshbhai Bhatt as the Additional Director (Independent), Mr. Dhairyakumar Mohanbhai Thakkar as the Additional Director (Independent), Mrs. Dharaben Piyushkumar Patel, as the Additional Director (Non-Executive), effective from July 17, 2024. Mr. Chintan Umeshbhai Bhatt is Practicing Company Secretary. He is Associate memberof the Institute of Company Secretaries of India. He is Bachelor of Law (LL.B.), Commerce graduate (B.Com), Diploma in Tax Practice (DTP) and Diploma in Labour Practice (DLP) awarded by Gujarat University. He is having more than 4 years of experience in the field of Corporate Law and Advisory Services. Mr. Dhairyakumar Mohanbhai Thakkar is a Qualified Company Secretary from the Institute of Company Secretaries of India. He has an experience of more than 10 years in the field of Company Law matters and other corporate matters. Mrs. Dharaben Piyushkumar Patel is a commerce graduate with more than 10 years of experience in the business administration and business management. Terms of Appointment: To hold office till the upcoming Annual General Meeting of the company.
공고 • Jul 15Sarda Proteins Ltd Announces Resignation of Shipra Gandhi as Chief Financial OfficerSarda Proteins Ltd. has received resignation letter dated 15t July, 2024 from Mrs. Shipra Gandhi, Chief Financial Officer (CFO) of the company informing about her resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from the closure of business hours of 15th July, 2024.
공고 • Jun 25Sarda Proteins Ltd Appoints Khilan Hareshbhai Savaliya as Additional Director (Non-Executive)Sarda Proteins Ltd. at its board of directors meeting held on June 24, 2024, approved appointment of Mr. Khilan Hareshbhai Savaliya (DIN: 08790209) as the Additional Director (Non-Executive)' of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, with effect from 24th day of June, 2024. Terms of Appointment: To hold office till the ensuing Annual General Meetingof the company. With an experience of 3+ years in the field of Turnkey Project Management, Mr. Khilan Hareshbhai Savaliya brings a wealth of knowledge and productivity to the organization.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mahavir Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • May 31Sarda Proteins Ltd Appoints Chirag Shantilal Thumar as Additional Executive DirectorSarda Proteins Ltd. Board of Directors of the Company in meeting held on 28 day of May, 2024, approved the appointment of Mr. Chirag Shantilal Thumar as the Additional Director (Executive) of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, effective 28th May, 2024.
Recent Insider Transactions • May 28MD & Director recently sold ₹3.0m worth of stockOn the 24th of May, Deepak Data sold around 35k shares on-market at roughly ₹84.58 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Deepak's only on-market trade for the last 12 months.
Reported Earnings • May 02Full year 2024 earnings released: EPS: ₹0.11 (vs ₹0.19 loss in FY 2023)Full year 2024 results: EPS: ₹0.11 (up from ₹0.19 loss in FY 2023). Revenue: ₹14.6m (down 75% from FY 2023). Net income: ₹194.0k (up ₹524.3k from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Apr 22Sarda Proteins Ltd to Report Q4, 2024 Results on Apr 30, 2024Sarda Proteins Ltd announced that they will report Q4, 2024 results on Apr 30, 2024
Board Change • Feb 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.04 (vs ₹0.01 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.04 (up from ₹0.01 in 3Q 2023). Revenue: ₹10.4m (down 54% from 3Q 2023). Net income: ₹69.0k (up 306% from 3Q 2023). Profit margin: 0.7% (up from 0.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 06Sarda Proteins Ltd to Report Q3, 2024 Results on Feb 13, 2024Sarda Proteins Ltd announced that they will report Q3, 2024 results on Feb 13, 2024
공고 • Nov 10Sarda Proteins Ltd Announces Resignation of Somya Data as Chief Financial OfficerSarda Proteins Ltd. announced that it has received Resignation letter dated 08t November, 2023. from. Mr. Somya Data, Chief Financial Officer (CFO) of the Company informing about his resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from closure of business hours of November 30, 2023.
Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹0.03 loss per share (vs ₹0.02 profit in 2Q 2023)Second quarter 2024 results: ₹0.03 loss per share (down from ₹0.02 profit in 2Q 2023). Revenue: ₹413.0k (down 99% from 2Q 2023). Net loss: ₹51.0k (down 289% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Oct 31Sarda Proteins Ltd to Report Q2, 2024 Results on Nov 07, 2023Sarda Proteins Ltd announced that they will report Q2, 2024 results on Nov 07, 2023
공고 • Aug 16Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.
공고 • Aug 08Sarda Proteins Ltd to Report Q1, 2024 Results on Aug 14, 2023Sarda Proteins Ltd announced that they will report Q1, 2024 results on Aug 14, 2023
New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹58m revenue, or US$706k). Market cap is less than US$10m (₹79.4m market cap, or US$967.3k). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
Reported Earnings • Jun 04Full year 2023 earnings released: ₹0.19 loss per share (vs ₹1.78 profit in FY 2022)Full year 2023 results: ₹0.19 loss per share (down from ₹1.78 profit in FY 2022). Revenue: ₹59.6m (down 45% from FY 2022). Net loss: ₹331.0k (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 24Sarda Proteins Ltd to Report Q4, 2023 Results on May 30, 2023Sarda Proteins Ltd announced that they will report Q4, 2023 results on May 30, 2023
Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹55.35, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 91% over the past year.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹49.69, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 30x in the Consumer Retailing industry in India. Total returns to shareholders of 51% over the past year.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹56.55, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 418% over the past three years.
Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.32 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.01 (down from ₹0.32 in 3Q 2022). Revenue: ₹22.7m (down 17% from 3Q 2022). Net income: ₹17.0k (down 97% from 3Q 2022). Profit margin: 0.1% (down from 2.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jan 31Sarda Proteins Ltd Announces Chief Financial Officer ChangesBoard of Directors of the Sarda Proteins Ltd, at its meeting held on, 30th January, 2023 has appointed Mr. Somya Data as the Chief Financial Officer (CFO) of the Company with effect from 01st February, 2023. Reason for Change: Due to resignation tendered by Mr. Himanshu Gupta, the Board has decided to appoint Mr. Somya Data as the Chief Financial Officer (CFO) of the company. Date of Appointment: With effect from 01st February, 2023 Qualification and Professional Experience: He is a graduate in Commerce from University of Rajasthan and is also CMA-Inter qualified from the Institute of Cost Accountants of India. He hasimmense knowledge of Financial Planning, Management of Financial Risks, Book Keeping, Financial Reporting, Indian Accounting Standards and Cost Accounting Standards.
공고 • Jan 24Sarda Proteins Ltd to Report Q3, 2023 Results on Jan 30, 2023Sarda Proteins Ltd announced that they will report Q3, 2023 results on Jan 30, 2023
공고 • Jan 20Sarda Proteins Ltd Announces Resignation of Himanshu Gupta as Chief Financial Officer, Effective 30 January 2023Sarda Proteins Ltd. announced that the company has received resignation letter dated 19 January 2023 from Mr. Himanshu Gupta, chief financial officer (CFO) of the company informing about his resignation from the post of chief financial officer (CFO) due to some personal reasons with effect from closure of business hours of 30 January 2023.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹60.35, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 453% over the past three years.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹90.90, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 41x in the Consumer Retailing industry in India. Total returns to shareholders of 732% over the past three years.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹123, the stock trades at a trailing P/E ratio of 60.4x. Average trailing P/E is 45x in the Consumer Retailing industry in India. Total returns to shareholders of 1,029% over the past three years.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹163, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 37x in the Consumer Retailing industry in India. Total returns to shareholders of 1,390% over the past three years.
Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.14 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (up from ₹0.14 loss in 2Q 2022). Revenue: ₹27.9m (up 274% from 2Q 2022). Net income: ₹27.0k (up ₹266.0k from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 161% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Oct 13Sarda Proteins Ltd to Report Q2, 2023 Results on Oct 19, 2022Sarda Proteins Ltd announced that they will report Q2, 2023 results on Oct 19, 2022
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.30, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 297% over the past three years.
공고 • Aug 06Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022, at 12:30 Indian Standard Time.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹32.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 27x in the Consumer Retailing industry in India. Total returns to shareholders of 213% over the past three years.
공고 • Jul 29Sarda Proteins Limited to Report Q1, 2023 Results on Aug 05, 2022Sarda Proteins Limited announced that they will report Q1, 2023 results on Aug 05, 2022
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 22x in the Consumer Retailing industry in India. Total returns to shareholders of 150% over the past three years.
공고 • May 19Sarda Proteins Limited to Report Q4, 2022 Results on May 27, 2022Sarda Proteins Limited announced that they will report Q4, 2022 results on May 27, 2022
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.17 loss in 3Q 2021). Revenue: ₹27.4m (up 492% from 3Q 2021). Net income: ₹560.0k (up ₹854.0k from 3Q 2021). Profit margin: 2.0% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates.
Board Change • Sep 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Jun 27Full year 2021 earnings released: ₹0.12 loss per share (vs ₹0.19 profit in FY 2020)The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: ₹114.4m (up 112% from FY 2020). Net loss: ₹202.0k (down 161% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹17.87, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 276% over the past three years.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹12.12, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 155% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.17 loss per share (vs ₹0.56 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.63m (down 67% from 3Q 2020). Net loss: ₹294.0k (down 131% from profit in 3Q 2020).
공고 • Feb 04Sarda Proteins Ltd. to Report Q3, 2021 Results on Feb 12, 2021Sarda Proteins Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021
Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 16% share price gain to ₹10.00, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 23x. This compares to an average P/E of 19x in the Consumer Retailing industry in India. Total return to shareholders over the past year is a loss of 8.4%.
공고 • Nov 03Sarda Proteins Ltd. to Report Q2, 2021 Results on Nov 09, 2020Sarda Proteins Ltd. announced that they will report Q2, 2021 results on Nov 09, 2020
공고 • Aug 25Sarda Proteins Ltd. to Report Q2, 2020 Results on Sep 02, 2020Sarda Proteins Ltd. announced that they will report Q2, 2020 results on Sep 02, 2020
